The clinical program has benefited from extensive European Union support, including the IMI2 TRIC-TB and UNITE4TB projects, as well as funding from the EDCTP2 bEto-TB project
The drug targets relapsed or refractory primary central nervous system lymphoma, a rare and aggressive form of non-Hodgkin lymphoma
Iberdomide has the potential to be the first approved CELMoD agent
This approval represents the seventh FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx with KEYTRUDA
The findings, based on an exploratory analysis, indicate that CD47 expression may predict which patients benefit most from the therapy
The approval is backed by data showing deep, durable responses and manageable tolerability
Tiger Shroff fronts ‘Fit Raho, Hit Raho’ campaign
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
Pembrolizumab has shown meaningful benefit only when combined with chemotherapy
Singh previously served as Head of IT (Development and Manufacturing Services) at Syngene International Limited, Lead of IT Manufacturing at UPL, and AGM at The Hi-Tech Gears
Subscribe To Our Newsletter & Stay Updated
